NewsRoom Articles - Page 117 of 591

TuesdayMar 07, 2023 10:30 am

India Globalization Capital Inc. (NYSE American: IGC) Focused on Fighting Alzheimer’s Disease with First-of-Kind Treatments in Study Phase

Government showing strong support for bills aimed at treating Alzheimer’s disease IGC’s leading drug candidate recently completed phase 1 of a safety and tolerability trial, and entered phase 2 Company’s proprietary treatments have “the potential to revolutionize the treatment of Alzheimer’s disease” Key legislation designed to fight Alzheimer’s has been introduced in Congress — or actually reintroduced: the NAPA Reauthorization Act was first introduced in the last Congress but is seeing continued support from the current group of elected officials (https://cnw.fm/xqOnK). Support for the treatment of Alzheimer’s is essential for organizations such as India Globalization Capital (NYSE American: IGC), a…

TuesdayMar 07, 2023 9:36 am

Lexaria Bioscience Corp. (NASDAQ: LEXX), a Global Innovator in Drug Delivery Platforms, Holds Discussions With Several Larger Companies on Path to Commercialization of DehydraTECH(TM) Technology

Lexaria’s patented DehydraTECH(TM) technology increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain absorption of active pharmaceutical ingredients The company out-licenses the use of its patented DehydraTECH(TM) technology within the pharmaceutical industry and consumer sectors Lexaria has focused on applied R&D to establish areas of investigation for commercial pursuits, with its programs proving successful Additionally, Lexaria has a robust intellectual property portfolio with 28 patents granted worldwide as of February 2023 In 2022, Lexaria Bioscience (NASDAQ: LEXX), a global innovator developing and commercializing its…

TuesdayMar 07, 2023 4:20 am

420 with CNW — Iowa Legislators File Adult-Use Cannabis Legalization Bill

On Feb. 21, 2023, Iowa Democratic legislators introduced a bill that would permit adult-use cannabis for recreational purposes. The proposed legislation would make it legal for adults 21 years and older with valid identification to possess cannabis with up to 500 milligrams of THC, the main psychoactive ingredient in cannabis. The legislation, which has yet to be formally brought to the House, also establishes a tax on authorized cannabis sales and lays the groundwork for regulated commercial marijuana sales. According to House Democratic Leader Jennifer Konfrst, Iowans of all political persuasions have voiced their strong support for legalizing marijuana, and…

MondayMar 06, 2023 4:20 pm

420 with CNW — Voters in Oklahoma to Decide Whether to Legalize Recreational Marijuana

Voters in Oklahoma are on track to vote on legislation that would legalize recreational cannabis in the state. On March 7, 2023, Oklahomans will get the chance to vote for or against state question 820, which asks if voters would like to expand the state’s medical cannabis industry to include adult-use cannabis. If Oklahomans vote in favor of the measure, Oklahoma will become the 22nd state in the nation to put a stop to marijuana prohibition. The measure comes close to five years after Oklahoma residents turned out in record numbers to vote in favor of legalizing medical cannabis. Activists…

MondayMar 06, 2023 4:20 am

420 with CNW — Alaskan Supreme Court Announces Plan to Expunge Cannabis Possession Criminal Records

The Alaska Supreme Court has announced that it would expunge cannabis convictions from the records of hundreds of Alaskans. An order signed by five Supreme Court justices revealed that the court would remove the cannabis possession convictions of 750 residents from the online court case database. However, rather than completely expunge certain cannabis records, the court will simply shield them from public view. So while the general public would likely find it hard to see these records, the records will still be accessible for inspection at courthouses and via formal criminal background checks. Only Alaskans who were aged 21 and…

FridayMar 03, 2023 10:30 am

India Globalization Capital Inc. (NYSE American: IGC) Leads the Way Forward with Revolutionary Cannabis-Based Treatment for Alzheimer’s Symptoms

Company’s investigational drug is being tested for the first time ever on humans in an FDA-approved study In phase 1 studies, IGC-AD1 shows potential to safely reduce debilitating symptoms IGC is actively building a portfolio of both cannabis-based and manufactured molecules that can address multiple areas of unmet medical needs In groundbreaking work that establishes its commitment to being a pioneer in the treatment of Alzheimer’s disease, India Globalization Capital (NYSE American: IGC) is developing a cannabis-based investigational drug that is being tested for the first time ever on humans in an FDA-approved study (https://cnw.fm/6qps2). The company is developing its…

FridayMar 03, 2023 4:20 am

420 with CNW — Arizona Records $1.4B in Cannabis Sales in 2022

The total marijuana sales in Arizona in 2022 were similar to those in 2021, the first year the drug was legal for adult use, but the routes by which each year's sales reached $1.4 billion were remarkably different. In 2021, medical cannabis sales accounted for $760 million, or nearly 55% of total sales. In 2022, recreational marijuana took the lead, accounting for roughly 70% of total sales, totaling more than $950 million. The medical cannabis market has dropped to just over $500 million. Recreational cannabis sales ended 2022 with its best monthly total in December, totaling about $86.6 million, a…

ThursdayMar 02, 2023 4:20 pm

420 with CNW — California’s Yearly Marijuana Sales Decline for First Time Since Launch of Recreational Market

New data from the California Department of Tax and Fee Administration shows that annual marijuana sales in the state dropped in 2022. This is the first time since the state launched its recreational market five years ago that sales have fallen. Last year, retailers raked in $5.3 billion in taxable sales of medical and recreational cannabis. This is quite a drop, in comparison to the $5.8 billion generated in 2021. Taxable sales in the fourth quarter also declined to $1.3 billion, down by almost 12% from the same period in 2021. Hirsh Jain, Ananda Strategy’s founder, stated that the continued…

ThursdayMar 02, 2023 1:33 pm

420 with CNW — SAMHSA Advisory Warns Users About CBD, Suggests Dispensary-Sourced Products Could Be Safer

The Substance Abuse and Mental Health Services Administration (SAMHSA), a branch of the U.S. Department of Health and Human Services, has released a new advisory warning about the possible side effects, harms, and unknowns of CBD. The federal agency also makes the implication that cannabis dispensaries may sell safer products than gas stations and other stores. The cannabinoid product has been available on store shelves since Congress approved the use of hemp in the 2018 Farm Act, and SAMHSA reports that demand for it is still rising. According to SAMHSA's advisory, a variety of form factors, such as CBD-infused foods,…

ThursdayMar 02, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Patented DehydraTECH(TM) Technology to Disrupt Drug Delivery Through Innovation

Lexaria's DehydraTECH(TM) technology has 28 granted patents, with many more patents pending worldwide DehydraTECH(TM) uses a patented formulation and dehydration process method to change how the body detects and absorbs drugs Lexaria is focusing on three main areas: CBD for hypertension, oral nicotine to replace vaping and smoking, and CBD potentially for diabetes and seizures Lexaria is conducting early work to support its FDA-registered IND program to investigate DehydraTECH(TM)-processed CBD for hypertension Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is increasing the bioavailability and improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through its…

News and publishing service for cannabis related companies

Contact us: 512.354.7000